Archive - November 2019
NHS workforce report shows ‘precarious’ positioning of organisation
New report shows ‘baby boom’ in life science ventures
ImmuPharma, Avion ink Lupuzor deal
NICE approves Ibrance via Cancer Drugs Fund
Merck’s Keytruda significantly extends life in some prostate cancer patients
Incyte claims FDA priority review for bile duct cancer drug
Labour clashes with government on ‘NHS for sale’ claims
Pfizer’s Ibrance scores second-line breast cancer approval via NICE’s Cancer Drugs Fund